Description
Survodutide is a dual glucagon and GLP-1 receptor agonist being developed for weight loss, obesity, and metabolic dysfunction-associated steatohepatitis (MASH). It works by acting on both the glucagon and GLP-1 receptors to reduce appetite, slow gastric emptying, and increase energy expenditure. Common side effects can include gastrointestinal issues like nausea and vomiting, but Phase 2 trials have shown significant weight loss and improvement in other conditions
